2M1L

Solution NMR Structure of Cyclin-dependent kinase 2-associated protein 2 (CDK2AP2, DOC-1R) from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8910C

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
2	2D 1H-13C HSQC	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
3	3D HNCO	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
4	3D CBCA(CO)NH	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
5	3D HNCACB	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
6	3D CBCA(CO)NH	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
7	3D HBHA(CO)NH	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
8	3D HN(CA)CO	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
9	3D 1H-13C NOESY aliphatic	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
10	3D 1H-15N NOESY	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
11	3D 13C-filtered NOESY aliphatic	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C, 15.0 mg/mL HR8910C, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O, 1 x Proteinase Inhibitors	95% H2O/5% D2O		6.5	ambient	298
12	2D 13C-filtered NOESY aromatic	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C, 15.0 mg/mL HR8910C, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O, 1 x Proteinase Inhibitors	95% H2O/5% D2O		6.5	ambient	298
13	2D 1H-13C high res (L/V methyl stereospecific assignment)	5.0 mg/mL [U-5% 13C; U-100% 15N] HR8910C.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
14	3D HCCH-TOCSY	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
15	3D HCCH-COSY	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
16	3D HCCH-TOCSY	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298
17	3D 1H-13C NOESY aromatic	5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O	95% H2O/5% D2O		6.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	800

NMR Refinement
Method	Details	Software
simulated annealing	Structure determination of this symmetric homodimer was performed iteratively using CYANA 3.02. The 20 structures out of 100 with lowest target function were further refined by restrained molecular dynamics/energy minimization in explicit water using CNS 1.3. Residual dipolar couplings and backbone dihedral angle constraints for the ordered regions were applied at all stages of the structure determination	CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement,structure solution,geometry optimization	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read
2	refinement,geometry optimization,structure solution	CYANA	3.02	Guntert, Mumenthaler and Wuthrich
3	data analysis,chemical shift assignment	AutoAssign	2.1	Zimmerman, Moseley, Kulikowski and Montelione
4	processing	NMRPipe	2.0	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
5	collection	TopSpin	2.1	Bruker Biospin
6	chemical shift assignment	PINE	1.0	Bahrami, Markley, Assadi, and Eghbalnia
7	data analysis	Sparky	3.112	Goddard
8	geometry optimization	TALOS+		Shen, Cornilescu, Delaglio and Bax
9	geometry optimization	PALES		PALES (Zweckstetter, Bax)
10	structure validation	PSVS	1.4	Bhattacharya, Montelione
11	refinement	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.